MiMedx Group Stock Price, News & Analysis (NASDAQ:MDXG)

$11.10 0.23 (2.12 %)
(As of 11/24/2017 04:00 PM ET)
Previous Close$10.87
Today's Range$10.72 - $11.15
52-Week Range$7.64 - $17.47
Volume635,840 shs
Average Volume1.73 million shs
Market Capitalization$1.23 billion
P/E Ratio51.76
Dividend YieldN/A
Beta0.91

About MiMedx Group (NASDAQ:MDXG)

MiMedx Group logoMiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

Receive MDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:MDXG
CUSIPN/A
Phone+1-678-3846720

Debt

Debt-to-Equity RatioN/A
Current Ratio3.25%
Quick Ratio2.95%

Price-To-Earnings

Trailing P/E Ratio51.76
Forward P/E Ratio46.25
P/E Growth2.59

Sales & Book Value

Annual Sales$245.01 million
Price / Sales5.03
Cash Flow$0.19 per share
Price / Cash59.81
Book Value$1.28 per share
Price / Book8.67

Profitability

Trailing EPS$0.30
Net Income$11.97 million
Net Margins11.64%
Return on Equity17.49%
Return on Assets12.69%

Miscellaneous

Employees690
Outstanding Shares111,040,000

Frequently Asked Questions for MiMedx Group (NASDAQ:MDXG)

What is MiMedx Group's stock symbol?

MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."

How will MiMedx Group's stock buyback program work?

MiMedx Group announced that its Board of Directors has initiated a share repurchase program on Tuesday, October 10th 2017, which allows the company to buyback $10,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company's management believes its shares are undervalued.

How were MiMedx Group's earnings last quarter?

MiMedx Group, Inc (NASDAQ:MDXG) posted its quarterly earnings data on Thursday, October, 26th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.08. The medical equipment provider had revenue of $84.60 million for the quarter, compared to the consensus estimate of $84.60 million. MiMedx Group had a net margin of 11.64% and a return on equity of 17.49%. The business's revenue was up 31.4% on a year-over-year basis. During the same period last year, the business earned $0.06 earnings per share. View MiMedx Group's Earnings History.

What guidance has MiMedx Group issued on next quarter's earnings?

MiMedx Group updated its FY17 earnings guidance on Thursday, October, 26th. The company provided earnings per share guidance of $0.31-0.32 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.32. The company issued revenue guidance of $320.6-$321.6 million, compared to the consensus revenue estimate of $312.23 million.

Where is MiMedx Group's stock going? Where will MiMedx Group's stock price be in 2017?

4 analysts have issued 12-month price objectives for MiMedx Group's stock. Their forecasts range from $11.00 to $21.00. On average, they expect MiMedx Group's stock price to reach $17.00 in the next twelve months. View Analyst Ratings for MiMedx Group.

What are Wall Street analysts saying about MiMedx Group stock?

Here are some recent quotes from research analysts about MiMedx Group stock:

  • 1. According to Zacks Investment Research, "MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant. " (10/10/2017)
  • 2. Needham & Company LLC analysts commented, "MDXG announced very positive results from its Phase 2B trial of AmnioFix Injectable in plantar fasciitis and has now initiated its Phase 3 trial in support of a BLA with patient enrollment expected to begin in the next 30-60 days. Since AmnioFix Injectable is currently commercially available as a 361 HCT/P product, we expect the Phase 2B results to drive increased sales of AmnioFix Injectable on an out- of-pocket basis even before a BLA is obtained. We estimate that MDXG could complete the plantar fasciitis BLA in 2020. MDXG estimates that the US plantar fasciitis potential annual market is $450M. We also think that the plantar fasciitis trial results bode well for MDXG’s other clinical programs including: knee pain, knee osteoarthritis, and achilles tendonitis. Even with the large move MDXG shares have had recently, we do not believe that its current valuation gives it much, if any, credit for its biopharmaceutical pipeline." (8/3/2017)

Are investors shorting MiMedx Group?

MiMedx Group saw a increase in short interest in October. As of October 31st, there was short interest totalling 36,722,876 shares, an increase of 11.4% from the October 13th total of 32,973,674 shares. Based on an average trading volume of 3,534,174 shares, the short-interest ratio is presently 10.4 days. Approximately 35.8% of the company's shares are short sold.

Who are some of MiMedx Group's key competitors?

Who are MiMedx Group's key executives?

MiMedx Group's management team includes the folowing people:

  • Parker H. Petit Jr., Chairman of the Board, Chief Executive Officer (Age 77)
  • William Charles Taylor, President, Chief Operating Officer, Director (Age 48)
  • Michael J. Senken, Chief Financial Officer (Age 58)
  • Alexandra O. Haden, General Counsel, Secretary (Age 42)
  • Charles E. Koob, Director (Age 72)
  • Luis A. Aguilar, Independent Director (Age 63)
  • Joseph G. Bleser, Independent Director (Age 71)
  • J. Terry Dewberry, Independent Director (Age 73)
  • Charles R. Evans, Independent Director (Age 70)

Who owns MiMedx Group stock?

MiMedx Group's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Macquarie Group Ltd. (1.57%), Bank of New York Mellon Corp (1.22%), Prudential Financial Inc. (1.00%), Stephens Investment Management Group LLC (0.89%), Wells Fargo & Company MN (0.64%) and Disciplined Growth Investors Inc. MN (0.63%). Company insiders that own MiMedx Group stock include Parker H Petit and William Charles Taylor. View Institutional Ownership Trends for MiMedx Group.

Who sold MiMedx Group stock? Who is selling MiMedx Group stock?

MiMedx Group's stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Merriman Wealth Management LLC, Stephens Investment Management Group LLC, Rice Hall James & Associates LLC, Dupont Capital Management Corp, Great West Life Assurance Co. Can, Disciplined Growth Investors Inc. MN and Thompson Investment Management Inc.. View Insider Buying and Selling for MiMedx Group.

Who bought MiMedx Group stock? Who is buying MiMedx Group stock?

MiMedx Group's stock was bought by a variety of institutional investors in the last quarter, including Prudential Financial Inc., American Century Companies Inc., Robeco Institutional Asset Management B.V., Old Mutual Global Investors UK Ltd., Schwab Charles Investment Management Inc., Mckinley Capital Management LLC Delaware, Wildcat Capital Management LLC and Point72 Asset Management L.P.. View Insider Buying and Selling for MiMedx Group.

How do I buy MiMedx Group stock?

Shares of MiMedx Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MiMedx Group's stock price today?

One share of MiMedx Group stock can currently be purchased for approximately $11.10.

How big of a company is MiMedx Group?

MiMedx Group has a market capitalization of $1.23 billion and generates $245.01 million in revenue each year. The medical equipment provider earns $11.97 million in net income (profit) each year or $0.30 on an earnings per share basis. MiMedx Group employs 690 workers across the globe.

How can I contact MiMedx Group?

MiMedx Group's mailing address is 1775 W Oak Commons Ct, MARIETTA, GA 30062-2254, United States. The medical equipment provider can be reached via phone at +1-678-3846720 or via email at [email protected]


MarketBeat Community Rating for MiMedx Group (MDXG)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  251 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  374
MarketBeat's community ratings are surveys of what our community members think about MiMedx Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for MiMedx Group (NASDAQ:MDXG)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.222.302.332.44
Ratings Breakdown: 3 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
2 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.83$14.83$14.67$11.63
Price Target Upside: 24.34% upside26.56% upside5.50% downside18.88% downside

Consensus Price Target History for MiMedx Group (NASDAQ:MDXG)

Price Target History for MiMedx Group (NASDAQ:MDXG)

Analysts' Ratings History for MiMedx Group (NASDAQ:MDXG)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/14/2017Needham & Company LLCReiterated RatingBuy$21.00N/AView Rating Details
8/20/2017Piper Jaffray CompaniesReiterated RatingBuy$18.00LowView Rating Details
7/28/2017Lake Street CapitalBoost Price TargetBuy$16.00 -> $18.00HighView Rating Details
5/23/2017First AnalysisDowngradeEqual Weight -> Underweight$11.00HighView Rating Details
11/7/2016AegisInitiated CoverageBuy$12.00N/AView Rating Details
6/29/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
1/13/2016Canaccord GenuityReiterated RatingBuy$12.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for MiMedx Group (NASDAQ:MDXG)

Earnings by Quarter for MiMedx Group (NASDAQ:MDXG)

Earnings History by Quarter for MiMedx Group (NASDAQ MDXG)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2017Q3 2017$0.08$0.08$84.60 million$84.60 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.07$0.07$74.22 million$76.40 millionViewN/AView Earnings Details
4/28/2017Q1 2017$0.07$0.07$72.60 million$72.60 millionViewN/AView Earnings Details
2/23/2017Q416$0.08$0.05$71.13 million$69.90 millionViewListenView Earnings Details
10/27/2016Q316$0.06$0.06$63.18 million$64.40 millionViewListenView Earnings Details
7/26/2016Q216$0.07$0.05$56.49 million$57.00 millionViewListenView Earnings Details
4/25/2016Q116$0.05$0.04$54.05 million$53.40 millionViewListenView Earnings Details
2/23/2016Q415$0.06$0.12$51.84 million$51.80 millionViewListenView Earnings Details
10/29/2015Q315$0.06$0.06$48.61 million$49.00 millionViewListenView Earnings Details
7/30/2015Q215$0.04$0.05$45.03 million$45.68 millionViewListenView Earnings Details
4/27/2015Q1$0.03$0.04$40.77 millionViewListenView Earnings Details
2/26/2015Q414$0.03$0.03$38.15 million$39.60 millionViewListenView Earnings Details
10/30/2014Q314$0.02$0.03$33.50 million$33.50 millionViewListenView Earnings Details
4/25/2014Q114($0.02)($0.01)$19.09 million$19.60 millionViewListenView Earnings Details
2/26/2014Q4($0.01)($0.04)$18.31 million$18.00 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.01)($0.01)$12.94 million$13.52 millionViewListenView Earnings Details
5/1/2013Q1 2013($0.02)($0.02)$11.34 million$11.56 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for MiMedx Group (NASDAQ:MDXG)
2017 EPS Consensus Estimate: $0.26
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.04$0.06$0.05
Q2 20172$0.04$0.04$0.04
Q3 20171$0.07$0.07$0.07
Q4 20172$0.08$0.12$0.10
Q1 20181$0.06$0.06$0.06
(Data provided by Zacks Investment Research)

Dividends

Dividend History for MiMedx Group (NASDAQ:MDXG)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for MiMedx Group (NASDAQ MDXG)

Insider Ownership Percentage: 12.40%
Institutional Ownership Percentage: 62.24%
Insider Trades by Quarter for MiMedx Group (NASDAQ:MDXG)
Institutional Ownership by Quarter for MiMedx Group (NASDAQ:MDXG)

Insider Trades by Quarter for MiMedx Group (NASDAQ MDXG)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/14/2017William Charles TaylorInsiderSell80,000$14.52$1,161,600.00View SEC Filing  
5/25/2017William Charles TaylorInsiderSell26,571$13.74$365,085.54View SEC Filing  
4/27/2017William Charles TaylorInsiderSell26,000$11.40$296,400.00View SEC Filing  
9/6/2016William Charles TaylorInsiderSell20,400$7.55$154,020.00View SEC Filing  
8/1/2016William Charles TaylorInsiderSell29,112$7.55$219,795.60View SEC Filing  
6/16/2016William Charles TaylorCOOSell24,333$7.52$182,984.16View SEC Filing  
5/20/2016Parker H PetitCEOBuy20,000$6.99$139,800.00View SEC Filing  
5/17/2016Parker H PetitCEOBuy30,000$6.82$204,600.00View SEC Filing  
5/13/2016Parker H PetitCEOBuy40,000$6.75$270,000.00View SEC Filing  
5/12/2016Parker H PetitCEOBuy50,000$6.74$337,000.00View SEC Filing  
11/13/2015Charles Robert EvansDirectorBuy10,000$7.84$78,400.00View SEC Filing  
11/10/2015Parker H PetitCEOBuy131,925$7.58$999,991.50View SEC Filing  
10/30/2015Alexandra O. HadenGeneral CounselBuy4,150$7.92$32,868.00View SEC Filing  
5/28/2015Larry W PapasanDirectorSell5,958$10.09$60,116.22View SEC Filing  
5/18/2015William Charles TaylorCOOSell150,000$10.01$1,501,500.00View SEC Filing  
10/31/2014William Charles TaylorCOOSell150,000$10.01$1,501,500.00View SEC Filing  
7/1/2014William Charles TaylorCOOSell150,000$7.50$1,125,000.00View SEC Filing  
1/17/2014Parker PetitCEOSell150,000$8.28$1,242,000.00View SEC Filing  
8/28/2013William Charles TaylorCOOSell9,800$6.15$60,270.00View SEC Filing  
8/7/2013William Charles TaylorCOOSell183,765$6.21$1,141,180.65View SEC Filing  
5/16/2013Steve GorlinDirectorSell30,000$6.46$193,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for MiMedx Group (NASDAQ MDXG)

Source:
DateHeadline
ETFs with exposure to MiMedx Group, Inc. : November 24, 2017ETFs with exposure to MiMedx Group, Inc. : November 24, 2017
finance.yahoo.com - November 24 at 5:19 PM
First Week Of January 2018 Options Trading For MiMedx Group (MDXG)First Week Of January 2018 Options Trading For MiMedx Group (MDXG)
www.thestreet.com - November 23 at 5:14 PM
MiMedx down 5% on new Viceroy report of misconduct - Seeking AlphaMiMedx down 5% on new Viceroy report of misconduct - Seeking Alpha
seekingalpha.com - November 22 at 3:40 AM
MiMedx Provides Update On Its Reimbursement CoverageMiMedx Provides Update On Its Reimbursement Coverage
finance.yahoo.com - November 22 at 3:40 AM
MiMedx to Present at the 29th Annual Piper Jaffray Healthcare ConferenceMiMedx to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 22 at 3:40 AM
MiMedx Group, Inc (MDXG) Receives Average Recommendation of "Hold" from BrokeragesMiMedx Group, Inc (MDXG) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 19 at 12:16 PM
MiMedx Group (MDXG) Says its Leadership Well Positioned in Light Of FDA New Guidance Document; Reaffirms GuidanceMiMedx Group (MDXG) Says its Leadership Well Positioned in Light Of FDA New Guidance Document; Reaffirms Guidance
www.streetinsider.com - November 18 at 1:59 AM
MiMedx Group (MDXG) Presents At Jefferies 2017 London Healthcare Conference - SlideshowMiMedx Group (MDXG) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 17 at 3:57 PM
MiMedx Market Leadership Well Positioned In Light Of FDA New Guidance DocumentMiMedx Market Leadership Well Positioned In Light Of FDA New Guidance Document
finance.yahoo.com - November 17 at 3:57 PM
MiMedx Adds New Materials To Its Website Exposing Misinformation Disseminated Through Short SellersMiMedx Adds New Materials To Its Website Exposing Misinformation Disseminated Through Short Sellers
finance.yahoo.com - November 15 at 6:18 AM
MiMedx Group, Inc (MDXG) Given "Buy" Rating at Needham & Company LLCMiMedx Group, Inc (MDXG) Given "Buy" Rating at Needham & Company LLC
www.americanbankingnews.com - November 14 at 1:14 PM
MDXG January 2020 Options Begin TradingMDXG January 2020 Options Begin Trading
www.thestreet.com - November 13 at 8:51 PM
ETFs with exposure to MiMedx Group, Inc. : November 13, 2017ETFs with exposure to MiMedx Group, Inc. : November 13, 2017
finance.yahoo.com - November 13 at 3:51 PM
MiMedx Group, Inc (MDXG) Short Interest UpdateMiMedx Group, Inc (MDXG) Short Interest Update
www.americanbankingnews.com - November 11 at 3:40 AM
MiMedx to Present at Jefferies 2017 London Healthcare ConferenceMiMedx to Present at Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 8 at 5:40 PM
MiMedx To Webcast Its Investors Day Conference on November 30, 2017MiMedx To Webcast Its Investor's Day Conference on November 30, 2017
finance.yahoo.com - November 8 at 5:40 PM
Stocks Showing Improved Relative Strength: MiMedxStocks Showing Improved Relative Strength: MiMedx
finance.yahoo.com - November 7 at 6:47 AM
 Brokerages Anticipate MiMedx Group, Inc (MDXG) Will Post Earnings of $0.10 Per Share Brokerages Anticipate MiMedx Group, Inc (MDXG) Will Post Earnings of $0.10 Per Share
www.americanbankingnews.com - November 6 at 1:18 AM
MiMedx Group, Inc. :MDXG-US: Earnings Analysis: Q3, 2017 By the Numbers : November 2, 2017MiMedx Group, Inc. :MDXG-US: Earnings Analysis: Q3, 2017 By the Numbers : November 2, 2017
finance.yahoo.com - November 3 at 5:01 PM
MiMedx To Present At The Canaccord|Genuity Medical Technology And Diagnostics ForumMiMedx To Present At The Canaccord|Genuity Medical Technology And Diagnostics Forum
finance.yahoo.com - November 3 at 5:01 PM
ETFs with exposure to MiMedx Group, Inc. : November 3, 2017ETFs with exposure to MiMedx Group, Inc. : November 3, 2017
finance.yahoo.com - November 3 at 5:01 PM
MiMedx Group (MDXG) Settles Lawsuit with Halo Wound Solutions - StreetInsider.comMiMedx Group (MDXG) Settles Lawsuit with Halo Wound Solutions - StreetInsider.com
www.streetinsider.com - November 2 at 6:18 AM
MiMedx Agrees To Lawsuit Settlement With Halo Wound SolutionsMiMedx Agrees To Lawsuit Settlement With Halo Wound Solutions
finance.yahoo.com - November 2 at 6:18 AM
IBD Rating Upgrades: MiMedx Shows Improved Technical StrengthIBD Rating Upgrades: MiMedx Shows Improved Technical Strength
finance.yahoo.com - November 1 at 6:10 AM
MiMedx CEO Replies to Fraudulent Information About The CompanyMiMedx CEO Replies to Fraudulent Information About The Company
finance.yahoo.com - October 31 at 5:16 AM
MiMedx Group Investor Reminder and Update: Hagens Berman Reminds MiMedx Group Investors of Investigation into Possible Securities Law Violations Related to Report Questioning MiMedxs Accounting Practices and Alerts Them to Recent Claims of Potential Accounting IrregularitiesMiMedx Group Investor Reminder and Update: Hagens Berman Reminds MiMedx Group Investors of Investigation into Possible Securities Law Violations Related to Report Questioning MiMedx's Accounting Practices and Alerts Them to Recent Claims of Potential Accounting Irregularities
finance.yahoo.com - October 31 at 5:15 AM
MiMedx Group (MDXG) Says Its Aware of Short Seller Website Dedicated to Posting Defamatory and False Information - StreetInsider.comMiMedx Group (MDXG) Says It's Aware of Short Seller Website Dedicated to Posting Defamatory and False Information - StreetInsider.com
www.streetinsider.com - October 30 at 12:35 AM
MiMedx Groups (MDXG) CEO Pete Petit on Q3 2017 Results ... - Seeking AlphaMiMedx Group's (MDXG) CEO Pete Petit on Q3 2017 Results ... - Seeking Alpha
seekingalpha.com - October 29 at 6:44 AM
MiMedx Group (MDXG) Says Its Aware of Short Seller Website Dedicated to Posting Defamatory and False InformationMiMedx Group (MDXG) Says It's Aware of Short Seller Website Dedicated to Posting Defamatory and False Information
www.streetinsider.com - October 28 at 8:05 AM
Stocks With Rising Relative Strength: MiMedxStocks With Rising Relative Strength: MiMedx
finance.yahoo.com - October 28 at 8:05 AM
MiMedx Exposes Content of a Short Seller Website Dedicated to Posting Defamatory and False Information About The CompanyMiMedx Exposes Content of a Short Seller Website Dedicated to Posting Defamatory and False Information About The Company
finance.yahoo.com - October 28 at 8:05 AM
Edited Transcript of MDXG earnings conference call or presentation 27-Oct-17 2:30pm GMTEdited Transcript of MDXG earnings conference call or presentation 27-Oct-17 2:30pm GMT
finance.yahoo.com - October 28 at 8:05 AM
Short Interest In MiMedx Group Increases 11.7%Short Interest In MiMedx Group Increases 11.7%
www.thestreet.com - October 27 at 6:48 AM
MiMedx Announces Record Results For Third Quarter Of 2017 And Raises Full Year Revenue GuidanceMiMedx Announces Record Results For Third Quarter Of 2017 And Raises Full Year Revenue Guidance
finance.yahoo.com - October 27 at 6:48 AM
MiMedx posts 3Q profitMiMedx posts 3Q profit
finance.yahoo.com - October 27 at 6:48 AM
MiMedx Group, Inc (MDXG) Announces Quarterly  Earnings ResultsMiMedx Group, Inc (MDXG) Announces Quarterly Earnings Results
www.americanbankingnews.com - October 26 at 10:56 PM
MiMedx Group, Inc (MDXG) Issues FY17 Earnings GuidanceMiMedx Group, Inc (MDXG) Issues FY17 Earnings Guidance
www.americanbankingnews.com - October 26 at 7:34 PM
Short Interest in MiMedx Group, Inc (MDXG) Expands By 11.7%Short Interest in MiMedx Group, Inc (MDXG) Expands By 11.7%
www.americanbankingnews.com - October 26 at 1:20 AM
MiMedx Group, Inc (MDXG) Receives Consensus Rating of "Hold" from AnalystsMiMedx Group, Inc (MDXG) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - October 25 at 2:55 PM
Citrons New Short Thesis On MiMedx Group, ExplainedCitron's New Short Thesis On MiMedx Group, Explained
www.benzinga.com - October 25 at 7:08 AM
MiMedx Group (MDXG) Says it Added New Materials to its Website Exposing Misinformation Disseminated Through Short Seller AttacksMiMedx Group (MDXG) Says it Added New Materials to its Website Exposing Misinformation Disseminated Through Short Seller Attacks
www.streetinsider.com - October 25 at 7:08 AM
MDXG INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of MiMedx Group, Inc. InvestorsMDXG INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of MiMedx Group, Inc. Investors
finance.yahoo.com - October 25 at 7:08 AM
Glancy Prongay & Murray LLP Commences Investigation on Behalf of MiMedx Group, Inc. Investors (MDXG)Glancy Prongay & Murray LLP Commences Investigation on Behalf of MiMedx Group, Inc. Investors (MDXG)
finance.yahoo.com - October 25 at 7:08 AM
Is MiMedx Group Inc (MDXG) As Financially Strong As Its Balance Sheet Indicates?Is MiMedx Group Inc (MDXG) As Financially Strong As Its Balance Sheet Indicates?
finance.yahoo.com - October 25 at 7:07 AM
MiMedx Group (MDXG) Shares Cross Below 200 DMAMiMedx Group (MDXG) Shares Cross Below 200 DMA
www.nasdaq.com - October 24 at 5:17 AM
Why MiMedx Group Inc. Is Sinking TodayWhy MiMedx Group Inc. Is Sinking Today
finance.yahoo.com - October 24 at 5:16 AM
New Clinical Evidence And A Landmark VLU Study To Be Presented At SAWC Fall MeetingNew Clinical Evidence And A Landmark VLU Study To Be Presented At SAWC Fall Meeting
finance.yahoo.com - October 19 at 6:13 AM
MiMedx Notified By FDA That It Can Proceed With Phase 2B Investigational New Drug Clinical Trial For Osteoarthritis Of The KneeMiMedx Notified By FDA That It Can Proceed With Phase 2B Investigational New Drug Clinical Trial For Osteoarthritis Of The Knee
finance.yahoo.com - October 18 at 6:54 AM
MiMedx Warns Of Fake EmailsMiMedx Warns Of Fake Emails
finance.yahoo.com - October 18 at 6:54 AM
MiMedx Group, Inc (MDXG) to Release Quarterly Earnings on WednesdayMiMedx Group, Inc (MDXG) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 18 at 5:38 AM

Social Media

Financials

Chart

MiMedx Group (NASDAQ MDXG) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.